87 related articles for article (PubMed ID: 16713718)
1. Glucagon challenge in the rat: a robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy.
Loxham SJ; Teague J; Poucher SM; De Schoolmeester J; Turnbull AV; Carey F
J Pharmacol Toxicol Methods; 2007; 55(1):71-7. PubMed ID: 16713718
[TBL] [Abstract][Full Text] [Related]
2. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
Andersen B; Westergaard N
Biochem J; 2002 Oct; 367(Pt 2):443-50. PubMed ID: 12099891
[TBL] [Abstract][Full Text] [Related]
3. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
Gregus Z; Németi B
Toxicol Sci; 2007 Nov; 100(1):44-53. PubMed ID: 17693424
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
Mackay P; Ynddal L; Andersen JV; McCormack JG
Diabetes Obes Metab; 2003 Nov; 5(6):397-407. PubMed ID: 14617225
[TBL] [Abstract][Full Text] [Related]
5. Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.
Fosgerau K; Westergaard N; Quistorff B; Grunnet N; Kristiansen M; Lundgren K
Arch Biochem Biophys; 2000 Aug; 380(2):274-84. PubMed ID: 10933882
[TBL] [Abstract][Full Text] [Related]
6. Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes.
Latsis T; Andersen B; Agius L
Biochem J; 2002 Nov; 368(Pt 1):309-16. PubMed ID: 12186629
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-D-arabinitol.
Andersen B; Rassov A; Westergaard N; Lundgren K
Biochem J; 1999 Sep; 342 Pt 3(Pt 3):545-50. PubMed ID: 10477265
[TBL] [Abstract][Full Text] [Related]
8. Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration.
Taguchi T; Yamashita E; Mizutani T; Nakajima H; Yabuuchi M; Asano N; Miwa I
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E534-40. PubMed ID: 15536204
[TBL] [Abstract][Full Text] [Related]
9. An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.
Poucher SM; Freeman S; Loxham SJ; Convey G; Bartlett JB; De Schoolmeester J; Teague J; Walker M; Turnbull AV; Charles AD; Carey F; Berg S
Br J Pharmacol; 2007 Dec; 152(8):1239-47. PubMed ID: 17934512
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory properties of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives acting on glycogen metabolising enzymes.
Díaz-Lobo M; Concia AL; Gómez L; Clapés P; Fita I; Guinovart JJ; Ferrer JC
Org Biomol Chem; 2016 Sep; 14(38):9105-9113. PubMed ID: 27714243
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glycogen phosphorylase stimulates ventromedial hypothalamic nucleus AMP-activated protein kinase: Activity and neuronal nitric oxide synthase protein expression in male rats.
Alhamami HN; Alshamrani A; Briski KP
Physiol Rep; 2017 Dec; 5(23):. PubMed ID: 29199177
[TBL] [Abstract][Full Text] [Related]
12. Lack of hepatic "interregulation" during inhibition of glycogenolysis in a canine model.
Fosgerau K; Mittelman SD; Sunehag A; Dea MK; Lundgren K; Bergman RN
Am J Physiol Endocrinol Metab; 2001 Aug; 281(2):E375-83. PubMed ID: 11440915
[TBL] [Abstract][Full Text] [Related]
13. Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge.
Lockton JA; Poucher SM
J Pharmacol Toxicol Methods; 2007; 55(1):86-90. PubMed ID: 16716604
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycogenolysis in astrocytes interrupts memory consolidation in young chickens.
Gibbs ME; Anderson DG; Hertz L
Glia; 2006 Aug; 54(3):214-22. PubMed ID: 16819764
[TBL] [Abstract][Full Text] [Related]
15. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
Floettmann E; Gregory L; Teague J; Myatt J; Hammond C; Poucher SM; Jones HB
Toxicol Pathol; 2010 Apr; 38(3):393-401. PubMed ID: 20215584
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes.
Zibrova D; Grempler R; Streicher R; Kauschke SG
Biochem J; 2008 Jun; 412(2):359-66. PubMed ID: 18298402
[TBL] [Abstract][Full Text] [Related]
17. Characterization of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) as an inhibitor of brain glycogen shunt activity.
Walls AB; Sickmann HM; Brown A; Bouman SD; Ransom B; Schousboe A; Waagepetersen HS
J Neurochem; 2008 May; 105(4):1462-70. PubMed ID: 18221367
[TBL] [Abstract][Full Text] [Related]
18. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
[TBL] [Abstract][Full Text] [Related]
19. Evidence against glycogen cycling of gluconeogenic substrates in various liver preparations.
Fosgerau K; Breinholt J; McCormack JG; Westergaard N
J Biol Chem; 2002 Aug; 277(32):28648-55. PubMed ID: 12042303
[TBL] [Abstract][Full Text] [Related]
20. Glycogen is a preferred glutamate precursor during learning in 1-day-old chick: biochemical and behavioral evidence.
Gibbs ME; Lloyd HG; Santa T; Hertz L
J Neurosci Res; 2007 Nov; 85(15):3326-33. PubMed ID: 17455305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
